Tipos de Cancer   /   Cánceres Ginecológicos   /   Cáncer del Ovario   /   Recursos de NCI

NCI/PDQ^® Health professionals: Ovarian Cancer Prevention (PDQ®)

National Cancer Institute
Ultima Vez Modificado: 6 de febrero del 2012

TABLE OF CONTENTS

• Summary of Evidence
  • Oral Contraceptives: Benefits
  • Oral Contraceptives: Harms
  • Prophylactic Oophorectomy: Benefits
  • Prophylactic Oophorectomy: Harms

• Significance
  • Incidence and Mortality

• Evidence of Benefit
  • Pathogenesis
  • Protective Factors
    • Oral contraceptives
    • Tubal sterilization
    • Prophylactic oophorectomy
  • Nonhereditary Factors Associated With an Increased Risk of Ovarian Cancer
    • Hormone replacement therapy/hormone therapy
    • Infertility treatment
    • Talc exposure
    • Height, weight, and dietary factors

• Changes to This Summary (02/06/2012)

• Questions or Comments About This Summary

• About This PDQ® Summary
  • Purpose of This Summary
  • Reviewers and Updates
  • Levels of Evidence
  • Permission to Use This Summary
  • Disclaimer
  • Contact Us

• Get More Information From NCI

Summary of Evidence

Note: Separate PDQ® summaries on Ovarian Cancer Screening and Ovarian Epithelial Cancer Treatment are also available.

Oral Contraceptives: Benefits

Based on solid evidence, oral contraceptive use is associated with a decreased risk of developing ovarian cancer.

Description of the Evidence
• Study Design: Evidence obtained from multiple case-control and cohort studies.
• Internal Validity: Good.
• Consistency: Good.
• Magnitude of Effects on Health Outcomes: A relative risk (RR) reduction of about 50% overall with a dose response ranging from 5% to 10% RR reduction per year of use to maximum RR reductions of up to 80%.
• External Validity: Good.

Oral Contraceptives: Harms

Based on solid evidence, combined current use of estrogen/progestogen oral contraceptive use is associated with an increased risk of venous thromboembolism. Oral contraceptives are not associated with a long-term increased risk of breast cancer but may be associated with a short-term increased risk while a woman is taking oral contraceptives. The risk of breast cancer declines with time since last use.

Description of the Evidence
• Study Design: Evidence obtained from observational studies.
• Internal Validity: Good.
• Consistency: Good.
• Magnitude of Effects on Health Outcomes: The risks may vary by preparation. Overall, the absolute risk of venous thromboembolism is about three events per 10,000 women per year while taking oral contraceptives. The risk is increased by smoking. Breast cancer risk among long-term (>10 years) current users is estimated at one extra case per year per 100,000 women. The risk dissipates with time since last use.
• External Validity: Good.

Prophylactic Oophorectomy: Benefits

Based on solid evidence, prophylactic bilateral oophorectomy is associated with a decreased risk of ovarian cancer. Peritoneal carcinomatosis has been reported following prophylactic removal of the ovaries. Prophylactic oophorectomy, along with salpingo-oophorectomy, is generally reserved for women at high risk of developing ovarian cancer, such as women who have a deleterious mutation in a BRCA1 or BRCA2 gene.

Description of the Evidence
• Study Design: Evidence obtained from multiple case-control and cohort studies.
• Internal Validity: Good.
• Consistency: Good.
• Magnitude of Effects on Health Outcomes: 90% reduction in risk of ovarian cancer observed among women with a BRCA1 or BRCA2 mutation.
• External Validity: Good.

Prophylactic Oophorectomy: Harms

Based on solid evidence, prophylactic oophorectomy among women who are still menstruating at the time of surgery is associated with infertility, vasomotor symptoms, decreased sexual interest, vaginal dryness, urinary frequency, decreased bone mineral density, and increased cardiovascular disease.

Description of the Evidence
• Study Design: Cohort and case-control studies.
• Internal Validity: Good.
• Consistency: Good.
• Magnitude of Effects on Health Outcomes: Reported prevalence of vasomotor symptoms varies from 41% to 61.4% among women who underwent oophorectomy prior to natural menopause. Women with bilateral oophorectomy who did not take hormone therapy were twice as likely to have moderate or severe hot flashes compared to women undergoing a natural menopause. The RR of cardiovascular disease among women with bilateral oophorectomy and early menopause was 4.55 (95% confidence interval, 2.569.01).
• External Validity: Good.

Significance

Incidence and Mortality

In 2012, it is estimated that 22,280 new cases of ovarian cancer will be diagnosed and 15,500 deaths due to ovarian cancer will occur. Incidence rates have been relatively stable since 1992. Death rates for ovarian cancer decreased by 1.9% per year from 2004 to 2008. 1

For the general population of women, the lifetime risk of developing ovarian cancer is 1.39%; the lifetime risk of dying from ovarian cancer is 1.04%. 2 Some women are at an increased risk due to an inherited susceptibility to ovarian cancer with the magnitude of that risk depending on the affected gene and specific mutation. Underlying ovarian cancer risk can be assessed through accurate pedigrees and/or genetic markers of risk. Because of uncertainties about cancer risks associated with specific gene mutations, genetic information may be difficult to interpret outside of families with a high incidence of ovarian cancer. Three inherited ovarian cancer susceptibility syndromes have been described: (1) familial site-specific ovarian cancer; (2) familial breast/ovarian cancer; and (3) Lynch II syndrome, which is a combination of breast, ovarian, endometrial, gastrointestinal, and genitourinary cancers. 3 4 Considering family history in the absence of specific information on BRCA1/2 mutation status, unaffected women who have two or three relatives with ovarian cancer have a cumulative ovarian cancer risk of about 7%. 3 5 Women who have a mother or sister with ovarian cancer have a cumulative lifetime risk of ovarian cancer of about 5%.

This summary does not address the groups that are at high risk due to inherited genetic factors. (Refer to the PDQ® summary on the Genetics of Breast and Ovarian Cancer for more information.)

References:

1. American Cancer Society.: Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society, 2012. Available online [PUBMED Abstract]
2. Altekruse SF, Kosary CL, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2007. Bethesda, Md: National Cancer Institute, 2010. Also available online [PUBMED Abstract]
3. Trimble EL, Karlan BY, Lagasse LD, et al.: Diagnosing the correct ovarian cancer syndrome. Obstet Gynecol 78 (6): 1023-6, 1991. [PUBMED Abstract]
4. Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 117--December 1992. Int J Gynaecol Obstet 41 (3): 321-3, 1993. [PUBMED Abstract]
5. Kerlikowske K, Brown JS, Grady DG: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 80 (4): 700-7, 1992. [PUBMED Abstract]

Evidence of Benefit

Pathogenesis

The pathogenesis of ovarian carcinoma remains unclear. Several theories have been proposed to explain the epidemiology of ovarian cancer including the theory of "incessant ovulation," 1 2 gonadotropin stimulation, 3 excess androgenic stimulation, 4 and inflammation. 5 Associated risk factors for ovarian cancer support some or all of these hypotheses. Oral contraceptive use is consistently associated with a decreased risk of ovarian cancer and may operate through preventing the trauma from repeated ovulation by lowering exposure to gonadotropins. No one theory, however, explains all the associated risk factors.

Protective Factors

Factors associated with a decreased risk of ovarian cancer include: (1) using oral contraceptives, (2) having and breastfeeding children, (3) having a bilateral tubal ligation or hysterectomy, and (4) having a prophylactic oophorectomy.

Oral contraceptives

Multiple studies have consistently demonstrated a decrease in ovarian cancer risk in women who take oral contraceptives. 6 7 The protective association increases with the duration of oral contraceptive use and persists up to 25 years after discontinuing oral contraceptives. A review of the literature demonstrated a 10% to 12% decrease in risk associated with use for 1 year and an approximate 50% decrease after 5 years of use. This reduced risk was present among both nulliparous and parous women. 6 A protective association between oral contraceptives and risk of ovarian cancer has been observed in most studies 8 9 10 among women who carry a mutation in BRCA1 and BRCA2 genes. A population-based study conducted in Israel did not observe an association between oral contraceptives and ovarian cancer, but parity was protective. 11

Tubal sterilization

In a prospective study, a 33% decrease in the risk of ovarian cancer among women who underwent tubal sterilization was observed after adjusting the data for oral contraceptive use, parity, and other ovarian cancer risk factors. This study also demonstrated a weaker, although statistically significant, decrease in risk associated with simple hysterectomy. 12

Prophylactic oophorectomy

Prophylactic oophorectomy may reduce the risk of developing ovarian cancer for women at high risk. One group for whom this option is considered is women who have an inherited susceptibility to ovarian cancer such as women who have mutations in BRCA1, BRCA2, or hereditary nonpolyposis colon cancer (HNPCC)associated genes. These women have a lifetime risk much higher than the general population, in the range of 20% to 60%. Evidence of the magnitude of risk reduction associated with bilateral oophorectomy comes primarily from studies of women with an inherited risk of cancer. A family-based study among women with BRCA1 or BRCA2 mutations found that of the 259 women who had undergone bilateral prophylactic oophorectomy, 2 (0.8%) developed subsequent papillary serous peritoneal carcinoma and 6 (2.8%) had stage I ovarian cancer at the time of surgery. Twenty-percent of the 292 matched controls who did not have prophylactic surgery developed ovarian cancer. Prophylactic surgery was associated with a greater than 90% reduction in the risk of ovarian cancer, (relative risk [RR] = 0.04; 95% confidence interval [CI], 0.010.16) with an average follow-up of 9 years; 13 however, family-based studies may be associated with biases due to case selection and other factors that may influence the estimate of benefit. 14 A study of 315 women with documented HNPCCassociated germline mutations found no ovarian cancer among 47 women who had bilateral salpingo-oophorectomy and 12 cases (5%) among women with mutations who had not had surgery for a prevented fraction of 100% (95% CI, 62%100%). Prophylactic surgery, however, is not 100% effective. Case reports and case series have reported the occurrence of peritoneal carcinomatosis following oophorectomy. 15 16 17

The degree of risk of ovarian cancer, potential morbidity and mortality of surgery, and the risks associated with early menopause, should be taken into account when considering prophylactic oophorectomy for high-risk women. Adverse effects of bilateral oophorectomy and premature menopause include infertility, vasomotor symptoms, decline in sexual interest and activity, cardiovascular disease, and osteoporosis. Among women who have not taken hormone therapy, women undergoing bilateral oophorecotmy were twice as likely to have moderate or severe hot flashes than women who underwent natural menopause (odds ratio [OR] = 2.44; 95% CI, 1.035.77). 18 Women at increased hereditary risk of ovarian cancer who underwent oophorectomy without hormone therapy reported statistically significantly more vasomotor symptoms than women choosing screening or those using hormone replacement therapy (HRT). 19 These women also reported lower sexual function scores but the difference was not statistically significant. 19 A meta-analysis of early menopause as a risk factor for cardiovascular disease observed a pooled risk of 4.55 (95% CI, 2.568.01) among women with bilateral oophorectomy and early menopause (defined as younger than 50 years). 20 Early menopause is also associated with an increased risk of fracture (OR = 1.5; 95% CI, 1.21.8). 21

Nonhereditary Factors Associated With an Increased Risk of Ovarian Cancer

Hormone replacement therapy/hormone therapy

Postmenopausal use of HRT, also called hormone therapy (HT), is associated with an increased risk of developing ovarian cancer. 22 23 24 The risk may vary by use of estrogen replacement therapy (ERT), also called estrogen therapy (ET), or estrogen-progestin replacement therapy (EPRT). A cohort study of women who participated in the Breast Cancer Detection Demonstration Project showed an increased risk of ovarian cancer associated with use of ERT/ET and ERT/ET followed by EPRT. A RR of 3.2 (95% CI, 1.75.7) was associated with 20 or more years use of ERT/ET only, with a statistically significant trend of increasing risk with increasing duration of use. Although no risk of ovarian cancer associated with EPRT use alone was observed, the number of women in this subgroup was small and an associated risk cannot be ruled out. 23 A case-control study of ovarian cancer also did not find an association between combined estrogen and progestin, but use of estrogen-only therapy for more than 10 years was associated with an increased risk. 25 An association between postmenopausal estrogen use and ovarian cancer mortality also has been shown. Vital status of 211,581 postmenopausal women, all of whom completed a baseline questionnaire in 1982 documenting no history of cancer, hysterectomy, or ovarian surgery was assessed through December 31, 1996. Women who were using estrogen at baseline had a significantly higher risk of ovarian cancer death than women who never used estrogen (RR = 1.51; 95% CI, 1.161.96). The risk increased with longer duration of use; women using estrogen at baseline and those who had used estrogen for at least 10 years had a higher risk of ovarian cancer death than did women who had never used estrogen, respectively (RR = 2.20; 95% CI, 1.533.17). 26

The largest double-blind randomized controlled trial of combined HRT/HT was the Women's Health Initiative (N = 16,608). This study found that, after an average follow-up of 5.6 years, women taking combined HRT/HT (compared with women randomly assigned to placebo) had a nonstatistically significant increased risk of invasive ovarian cancer (hazard ratio [HR] = 1.58; 0.773.24), with a wide confidence interval. 27

Infertility treatment

A collaborative analysis of case-control studies, analyzing data from 2,200 women with ovarian cancer and 8,900 control women from 12 U.S. studies, reported an association between fertility drug use and invasive ovarian cancer. 28 The use of fertility drugs was associated with an increased risk of ovarian cancer, primarily in women who did not have a subsequent pregnancy. Two case-control studies published subsequent to the collaborative analysis did not find an association between fertility drug use and risk of ovarian cancer. 29 30

A retrospective cohort study of women evaluated for infertility observed an increased risk of invasive or borderline malignant ovarian tumors associated with prolonged use of clomiphene. 31 Another retrospective cohort of more than 12,000 women evaluated for infertility found an increased risk of ovarian cancer compared with the general population (standardized incidence ratio 1.98; 95% CI, 1.42.6). There was no excess risk with the use of clomiphene or gonadotropins. Although the risks of ovarian cancer were slightly higher among women with 15 or more years from first exposure, the number of exposed cases were small (five exposed cases and three exposed cases, respectively) and observed rate ratios were not statistically significant.

Several other cohort studies of women undergoing infertility treatment have not observed an excess risk of ovarian cancer. 32 33 34 In one study, women with unexplained infertility who were not exposed to fertility drugs had an excess risk of ovarian and uterine cancers. 34

Talc exposure

A cohort study among nurses did not observe a risk of ovarian cancer associated with perineal talc use (RR = 1.09; 95% CI, 0.861.37). 35 A meta-analysis of 16 studies observed an increased risk with the use of talc (RR = 1.33; 95% CI, 1.161.45); however, there was no evidence of a dose response.

Height, weight, and dietary factors

Obesity is associated with an increased mortality from ovarian cancer. 36 In cohort studies, height and body mass index (BMI), 37 38 including high BMI during adolescence, 38 were associated with an increased risk of ovarian cancer, suggesting a role for diet and nutrition during the adolescent period.

Associations with specific dietary factors and ovarian cancer are not consistent among observational studies. 39 40 41 42 43 44 45 46 47

References:

1. Fathalla MF: Incessant ovulation--a factor in ovarian neoplasia? Lancet 2 (7716): 163, 1971. [PUBMED Abstract]
2. Riman T, Persson I, Nilsson S: Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf) 49 (6): 695-707, 1998. [PUBMED Abstract]
3. Cramer DW, Welch WR: Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71 (4): 717-21, 1983. [PUBMED Abstract]
4. Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (23): 1774-86, 1998. [PUBMED Abstract]
5. Ness RB, Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91 (17): 1459-67, 1999. [PUBMED Abstract]
6. Hankinson SE, Colditz GA, Hunter DJ, et al.: A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80 (4): 708-14, 1992. [PUBMED Abstract]
7. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 316 (11): 650-5, 1987. [PUBMED Abstract]
8. Whittemore AS, Balise RR, Pharoah PD, et al.: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91 (11): 1911-5, 2004. [PUBMED Abstract]
9. Gronwald J, Byrski T, Huzarski T, et al.: Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95 (2): 105-9, 2006. [PUBMED Abstract]
10. Narod SA, Sun P, Risch HA, et al.: Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 345 (23): 1706-7, 2001. [PUBMED Abstract]
11. Modan B, Hartge P, Hirsh-Yechezkel G, et al.: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345 (4): 235-40, 2001. [PUBMED Abstract]
12. Hankinson SE, Hunter DJ, Colditz GA, et al.: Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270 (23): 2813-8, 1993. [PUBMED Abstract]
13. Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002. [PUBMED Abstract]
14. Klaren HM, van't Veer LJ, van Leeuwen FE, et al.: Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 95 (13): 941-7, 2003. [PUBMED Abstract]
15. Tobacman JK, Greene MH, Tucker MA, et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 (8302): 795-7, 1982. [PUBMED Abstract]
16. Piver MS, Jishi MF, Tsukada Y, et al.: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (9): 2751-5, 1993. [PUBMED Abstract]
17. Casey MJ, Synder C, Bewtra C, et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 97 (2): 457-67, 2005. [PUBMED Abstract]
18. Gallicchio L, Whiteman MK, Tomic D, et al.: Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 85 (5): 1432-40, 2006. [PUBMED Abstract]
19. Madalinska JB, van Beurden M, Bleiker EM, et al.: The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24 (22): 3576-82, 2006. [PUBMED Abstract]
20. Atsma F, Bartelink ML, Grobbee DE, et al.: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13 (2): 265-79, 2006 Mar-Apr. [PUBMED Abstract]
21. van Der Voort DJ, van Der Weijer PH, Barentsen R: Early menopause: increased fracture risk at older age. Osteoporos Int 14 (6): 525-30, 2003. [PUBMED Abstract]
22. Garg PP, Kerlikowske K, Subak L, et al.: Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92 (3): 472-9, 1998. [PUBMED Abstract]
23. Lacey JV Jr, Mink PJ, Lubin JH, et al.: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (3): 334-41, 2002. [PUBMED Abstract]
24. Mills PK, Riordan DG, Cress RD, et al.: Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29 (2): 124-32, 2005. [PUBMED Abstract]
25. Moorman PG, Schildkraut JM, Calingaert B, et al.: Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 193 (1): 76-82, 2005. [PUBMED Abstract]
26. Rodriguez C, Patel AV, Calle EE, et al.: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (11): 1460-5, 2001. [PUBMED Abstract]
27. Anderson GL, Judd HL, Kaunitz AM, et al.: Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (13): 1739-48, 2003. [PUBMED Abstract]
28. Whittemore AS, Harris R, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136 (10): 1184-203, 1992. [PUBMED Abstract]
29. Parazzini F, Negri E, La Vecchia C, et al.: Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12 (10): 2159-61, 1997. [PUBMED Abstract]
30. Mosgaard BJ, Lidegaard O, Kjaer SK, et al.: Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 70 (6): 1049-55, 1998. [PUBMED Abstract]
31. Rossing MA, Daling JR, Weiss NS, et al.: Ovarian tumors in a cohort of infertile women. N Engl J Med 331 (12): 771-6, 1994. [PUBMED Abstract]
32. Dor J, Lerner-Geva L, Rabinovici J, et al.: Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 77 (2): 324-7, 2002. [PUBMED Abstract]
33. Doyle P, Maconochie N, Beral V, et al.: Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 17 (8): 2209-13, 2002. [PUBMED Abstract]
34. Venn A, Watson L, Bruinsma F, et al.: Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354 (9190): 1586-90, 1999. [PUBMED Abstract]
35. Gertig DM, Hunter DJ, Cramer DW, et al.: Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 92 (3): 249-52, 2000. [PUBMED Abstract]
36. Calle EE, Rodriguez C, Walker-Thurmond K, et al.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (17): 1625-38, 2003. [PUBMED Abstract]
37. Schouten LJ, Goldbohm RA, van den Brandt PA: Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol 157 (5): 424-33, 2003. [PUBMED Abstract]
38. Engeland A, Tretli S, Bjírge T: Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 95 (16): 1244-8, 2003. [PUBMED Abstract]
39. Genkinger JM, Hunter DJ, Spiegelman D, et al.: A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer. Cancer Causes Control 17 (3): 273-85, 2006. [PUBMED Abstract]
40. Genkinger JM, Hunter DJ, Spiegelman D, et al.: Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 15 (2): 364-72, 2006. [PUBMED Abstract]
41. Genkinger JM, Hunter DJ, Spiegelman D, et al.: Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. Br J Cancer 94 (5): 757-62, 2006. [PUBMED Abstract]
42. Mommers M, Schouten LJ, Goldbohm RA, et al.: Consumption of vegetables and fruits and risk of ovarian carcinoma. Cancer 104 (7): 1512-9, 2005. [PUBMED Abstract]
43. Larsson SC, Holmberg L, Wolk A: Fruit and vegetable consumption in relation to ovarian cancer incidence: the Swedish Mammography Cohort. Br J Cancer 90 (11): 2167-70, 2004. [PUBMED Abstract]
44. Kushi LH, Mink PJ, Folsom AR, et al.: Prospective study of diet and ovarian cancer. Am J Epidemiol 149 (1): 21-31, 1999. [PUBMED Abstract]
45. Fairfield KM, Hankinson SE, Rosner BA, et al.: Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 92 (9): 2318-26, 2001. [PUBMED Abstract]
46. Helzlsouer KJ, Alberg AJ, Norkus EP, et al.: Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst 88 (1): 32-7, 1996. [PUBMED Abstract]
47. Garland M, Morris JS, Stampfer MJ, et al.: Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87 (7): 497-505, 1995. [PUBMED Abstract]

Changes to This Summary (02/06/2012)

The PDQ® cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Significance

Updated statistics with estimated new cases and deaths for 2012 (cited American Cancer Society as reference 1).

This summary is written and maintained by the PDQ® Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ® Editorial Boards in maintaining the PDQ® summaries can be found on the About This PDQ® Summary and PDQ® NCI's Comprehensive Cancer Database pages.

Questions or Comments About This Summary

If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

About This PDQ® Summary

Purpose of This Summary

This PDQ® cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.

Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the PDQ® Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

• be discussed at a meeting,
• be cited with text, or
• replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ® Screening and Prevention Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.

Permission to Use This Summary

PDQ® is a registered trademark. Although the content of PDQ® documents can be used freely as text, it cannot be identified as an NCI PDQ® cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as NCI's PDQ® cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].

The preferred citation for this PDQ® summary is:

National Cancer Institute: PDQ® Ovarian Cancer Prevention. Bethesda, MD: National Cancer Institute. Date last modified . Available at: http://cancer.gov/cancertopics/pdq/prevention/ovarian/HealthProfessional. Accessed .

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ® summaries only. Permission to use images outside the context of PDQ® information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.

Disclaimer

The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Coping with Cancer: Financial, Insurance, and Legal Information page.

Contact Us

More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the Web site's Contact Form.

Get More Information From NCI

Call 1-800-4-CANCER

For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.

Chat online

The NCI's LiveHelp online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.

Write to us

For more information from the NCI, please write to this address:

• NCI Public Inquiries Office
• Suite 3036A
• 6116 Executive Boulevard, MSC8322
• Bethesda, MD 20892-8322

Search the NCI Web site

The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.

There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.

Find Publications

The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).